Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $161.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 37.48% year-over-year to $161.8 million; the TTM value through Dec 2025 reached $161.8 million, up 37.48%, while the annual FY2025 figure was $161.8 million, 37.48% up from the prior year.
  • Total Liabilities for Q4 2025 was $161.8 million at Vanda Pharmaceuticals, up from $135.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $161.8 million in Q4 2025 and bottomed at $75.6 million in Q1 2021.
  • The 5-year median for Total Liabilities is $105.0 million (2022), against an average of $108.0 million.
  • The largest annual shift saw Total Liabilities decreased 7.19% in 2023 before it soared 37.48% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $88.9 million in 2021, then grew by 20.46% to $107.0 million in 2022, then fell by 3.29% to $103.5 million in 2023, then rose by 13.65% to $117.7 million in 2024, then surged by 37.48% to $161.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Total Liabilities are $161.8 million (Q4 2025), $135.1 million (Q3 2025), and $138.4 million (Q2 2025).